The Board of Directors of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has with great pleasure appointed Dr. Mervyn Cass as a non-executive Director of the Company.

Dr. Cass is a practicing medical practitioner and, after 28 years as the senior partner in an occupational medical practice in Port Melbourne, accepted the appointment as Medical Director of a plastic surgery centre in 1996. He was the founding Chairman of the Australasian Occupational Medical Group and was a Director of Wolfe Research Pty. Ltd., a private medical biotech company associated with RMIT University. He has been an advisor to the Victorian Government on Workers’ Compensation and Radiological Standards in general practice. Dr. Cass is currently an executive member of the Jewish Community Council of Victoria, the roof body of the Victorian Jewish Community.

The Company’s Chairman Mr. Sid Hack said, “The Directors of Genetic Technologies are delighted that Mervyn has agreed to join the Board. His substantial experience in the fields of medicine, women’s health and restorative surgery will be of great practical and immediate value in the growth and development of the Company’s cancer diagnostics business. We very much look forward to working with Mervyn at this important time in the history of the Company.”

Copyright Business Wire 2010

If you liked this article you might like

5 Stocks Under $10 Set to Soar

5 Stocks Ready for Breakouts

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Stalking an Entry in RetailMeNot

Stalking an Entry in RetailMeNot

Why Genetic Technologies (GENE) Stock Is Spiking Today